Imatinib Mesylate (Gleevec) Hepatotoxicity
Authors:
- 12 January 2007
- journal article
- case report
- Published by Springer Nature in Digestive Diseases and Sciences
- Vol. 52 (2) , 598-601
Abstract
No abstract availableThis publication has 9 references indexed in Scilit:
- Imatinib (Gleevec)-induced hepatotoxicity.2005
- Severe Hepatitis and Complete Molecular Response Caused by Imatinib Mesylate: Possible Association of Its Serum Concentration with Clinical OutcomesLeukemia & Lymphoma, 2004
- Indications for Imatinib Mesylate Therapy and Clinical ManagementThe Oncologist, 2004
- Fatal hepatic necrosis following imatinib mesylate therapyBlood, 2003
- Approval summary: imatinib mesylate capsules for treatment of adult patients with newly diagnosed philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase.2003
- Histological features of acute hepatitis after imatinib mesylate treatmentLeukemia, 2003
- Imatinib mesylate-induced hepato-toxicity in chronic myeloid leukemia demonstrated focal necrosis resembling acute viral hepatitisLeukemia, 2002
- Approval summary for imatinib mesylate capsules in the treatment of chronic myelogenous leukemia.2002
- Efficacy and Safety of a Specific Inhibitor of the BCR-ABL Tyrosine Kinase in Chronic Myeloid LeukemiaNew England Journal of Medicine, 2001